Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Bioxyne Limited ( (AU:BXN) ) is now available.
Bioxyne Limited reported a record quarterly revenue of $9.5 million, marking a 204% increase from the previous year and a 33% rise from the previous quarter. The company also achieved positive cash flow from operating activities and exceeded its FY25 revenue guidance. A significant development is their entry into the German market through a €3.2 million manufacturing and supply agreement, which is expected to strengthen their operations in the EU/UK region. The company is poised for further growth with additional contracts anticipated in Europe and the UK.
More about Bioxyne Limited
Bioxyne Limited is an Australian life sciences, pharmaceutical, and consumer health products company. It is a leading manufacturer and wholesaler of novel medicines, including cannabis, MDMA, and Psilocybin, with a focus on rapidly growing markets in the UK and Europe.
Average Trading Volume: 4,088,725
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$93.09M
Find detailed analytics on BXN stock on TipRanks’ Stock Analysis page.